Guardian Pharmacy (GRDN) Q1 2026 earnings review
IRA Suppresses Revenue Growth, But Margins Prove Resilient
Guardian Pharmacy successfully absorbed the initial shockwaves of the Inflation Reduction Act (IRA). While mandated drug pricing resets crushed top-line momentum—driving revenue growth down to a decelerating 2% YoY—the company violently protected its profitability. Gross profit surged 18%, driving Net Income up 45% to $13.5M and Adjusted EBITDA up 27% to $29.8M. Management raised full-year EBITDA guidance, proving their local operator model and scale can generate expanding margins even when government policy artificially flatlines top-line growth.
🐂 Bull Case
Management promised they could offset IRA revenue headwinds with margin improvements, and they delivered. Gross margin expanded roughly 300 basis points YoY, driving a 27% Adjusted EBITDA gain on essentially flat sales.
The revenue slowdown is entirely pricing-driven. Underlying operational demand is stable, with residents served growing 10% YoY to 207,000, confirming the 'silver tsunami' demographic tailwind remains intact.
🐻 Bear Case
Operating cash flow is reversing, plunging 65% YoY to just $6.1M due to an $11.1M spike in Accounts Receivable. The transition to the government's new Medicare Transaction Facilitator may be tying up cash.
Selling, general, and administrative expenses grew 14% YoY to $58.6M. With revenue only growing 2%, this creates negative operating leverage if gross margins ever normalize.
⚖️ Verdict: 🟢
Bullish. The 2% revenue growth looks alarming in a vacuum, but it is precisely what management telegraphed regarding IRA impacts. Expanding EBITDA by 27% under these conditions is a massive operational victory.
Key Themes
Gross Margin Defies Revenue Stagnation
The most important data point of the quarter is the gross profit line. Despite revenue decelerating to 2% growth, Gross Profit accelerated by 18% YoY to $76.3M. This indicates that while the IRA forcibly lowered the gross revenue Guardian can claim for certain drugs, the underlying profitability of those scripts actually improved. Management noted a $3M pass-through benefit related to IRA inventory credits, but even excluding this, the core margin profile is structurally higher.
Cash Flow Reversing as Receivables Spike
While net income surged, cash conversion collapsed. Operating Cash Flow reversed from a healthy $17.6M in 25Q1 to just $6.1M this quarter. The culprit is working capital: Accounts Receivable increased by $11.1M in a single quarter, and Accounts Payable dropped by $7.8M. This is a classic red flag for collections delays, likely tied to the rollout of the government's new Medicare Transaction Facilitator (MTF) clearinghouse.
Consistent Volume Execution
The noise of the IRA pricing reset masks strong foundational growth. The company ended the quarter serving 207,000 residents, a 10% YoY increase. This stable, compounding growth in the underlying customer base ensures that once the IRA pricing adjustments are fully annualized by 2027, the company's revenue growth should mechanically snap back to high-single or low-double digits.
Gearing Up for Capital Allocation
Guardian is fortifying its balance sheet for potential action. The company completed an upsized, non-dilutive secondary offering of 6.9M shares in March to enhance liquidity, and immediately filed a new S-3 shelf registration. With $64.9M in cash and zero long-term debt on the credit facility, management is heavily armed for M&A if distressed competitors falter under the new IRA regulatory burdens.
Other KPIs
Accelerating significantly from prior periods. Adjusted EPS strips out $1.9M in share-based compensation (which has stabilized post-IPO) and the income tax impact, offering a cleaner look at the company's baseline profitability. The 40% premium of Adj EPS over GAAP EPS ($0.21) highlights the strong underlying cash-generation capacity of the business before working capital changes.
A notable point of friction. SG&A increased 14% YoY, heavily outpacing the 2% revenue growth. While part of this is due to new public company costs and acquisitions completed in mid-to-late 2025, it highlights a short-term deleveraging effect on the operating line that investors must monitor.
Guidance
Stable. The company maintained its full-year revenue outlook. This represents essentially flat growth compared to FY25, heavily suppressed by the IRA pricing mandates, but management expects to exit the year with normalized run rates.
Accelerating. Raised from the previous range of $120-$124 million. The $3 million boost directly reflects the discrete pass-through benefits and favorable payor dynamics captured in Q1. This implies a full-year margin of ~8.9%, up materially from 2025's 7.9% exit rate.
Key Questions
Accounts Receivable Build
Operating cash flow dropped significantly this quarter due to an $11.1M spike in accounts receivable. Is this a temporary delay caused by the rollout of the Medicare Transaction Facilitator, and when do you expect collections to normalize?
SG&A Leverage
SG&A grew 14% year-over-year while revenue grew only 2%. How much of this expense growth is structural versus temporary integration costs, and when should we expect SG&A growth to trail revenue growth again?
M&A Pipeline Visibility
With the new shelf registration filed and nearly $65 million in cash on the balance sheet, how has the IRA disruption affected the valuations of potential acquisition targets in your pipeline?